Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLF31907 in advanced cancer
NCT05150405Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Mar 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLF31907 in solid tumor and non-Hodgkin lymphoma (NHL), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-limiting toxicity at 28 days and Maximum tolerated dose up to 2 years. Started Oct 2021; status: recruiting.
02
Drugs
QLF31907
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05150405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05150405.